Post-stroke administration of ZT-1a showed inhibitory effect on WNK-SPAK-NKCC1 signaling cascade leading to neuroprotective outcome including reduction of cerebral infarct volume, swelling, white matter lesions and improvement of neurological function after ischemia (Zhang et al., 2020; Bhuiyan et al., 2022), suggesting ZT-1a has therapeutic potential against PSD. The gene discussed is SLC12A2; the disease is stroke disorder.